Stock AnalizBoston Scientific (BSX) earnings for the quarter ended September 2026: EPS beats estimates
Boston Scientific reported results for the quarter ended September 2026 on October 28, 2026. Adjusted earnings per share came in at $0.73 against the analysts’ average forecast of $0.72, a beat of 0.9%.
Revenue for the quarter was $5.14 billion, up 1.4% from $5.07 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 5.8% on the first trading day after the report.
The last four quarters
Boston Scientific has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.73 | $0.72 | +0.9% | +1% | −5.8% |
| Jun 2026 | $0.86 | $0.83 | +3.9% | +8% | −0.1% |
| Mar 2026 | $0.80 | $0.79 | +1.6% | +12% | +10.4% |
| Dec 2025 | $0.80 | $0.78 | +2.4% | +16% | −15.3% |
What comes next
Analysts expect EPS of $0.78 for the next quarter on average and $3.17 for the fiscal year ending December 31, 2026.
The average analyst price target is $49.60, 12% above the current price of $44.34.
Valuation and score
Boston Scientific scores 3.0 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 18.8, and its intrinsic value under moderate assumptions is about 58% below the current market value. Full Boston Scientific analysis with 10 years of financials
Frequently asked questions
What was Boston Scientific’s EPS for the quarter ended September 2026?
$0.73 adjusted per share, against an analyst consensus of $0.72.
How much revenue did Boston Scientific report?
$5.14 billion, up 1.4% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.